Prime Medicine
PRME
105 hedge funds and large institutions have $433M invested in Prime Medicine in 2023 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 26 increasing their positions, 27 reducing their positions, and 12 closing their positions.
183% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 12
27% more funds holding
Funds holding: 83 → 105 (+22)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.64% less ownership
Funds ownership: 50.89% → 50.25% (-0.64%)
4% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 27
8% less capital invested
Capital invested by funds: $472M → $433M (-$39M)
33% less call options, than puts
Call options by funds: $375K | Put options by funds: $558K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$3.97M |
| 2 |
BlackRock
New York
|
+$3.42M |
| 3 |
Morgan Stanley
New York
|
+$2.93M |
| 4 |
BG
Bollard Group
Boston,
Massachusetts
|
+$2.78M |
| 5 |
Two Sigma Investments
New York
|
+$1.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$12.8M |
| 2 |
State Street
Boston,
Massachusetts
|
-$7.14M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.72M |
| 4 |
MCM
Moore Capital Management
New York
|
-$4.26M |
| 5 |
Rafferty Asset Management
New York
|
-$1.23M |
PRME Hedge Fund Activity: Q4 2023 in Review
105 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q4 2023, worth a combined $433M — down 8.3% from $472M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new PRME positions and 12 closed out — a net gain of 22 holders — while 26 added to existing stakes and 27 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $3.97M. The largest seller was Fidelity International, cutting an estimated $12.8M.
- 105 institutional investors held Prime Medicine (PRME) as of Q4 2023, up from 83 in Q3 2023.
- Funds reported $433M of Prime Medicine stock for Q4 2023, down 8.3% quarter-over-quarter.
- 34 funds opened new Prime Medicine positions in Q4 2023 and 12 closed out, a net change of +22 holders.
- The largest Prime Medicine buyer in Q4 2023 was ARK Investment Management, an estimated $3.97M added.
- The largest Prime Medicine seller in Q4 2023 was Fidelity International, an estimated $12.8M sold.
Based on aggregated 13F filings for Q4 2023.